Colorectal cancer. New targeted EGFR chemotherapy options. 2

Leading colorectal cancer expert from Oxford discusses targeted chemotherapy progress in colorectal cancer treatment. From 5-fluorouracil to anti-angiogenesis medications. Which patients benefit most from targeted chemotherapy of colon cancer? How life expectancy has changed? What are new chemotherapy medications and treatment protocols?

Colorectal cancer new treatment options. Dr. Anton Titov, MD. EGFR and anti-angiogenesis targeted therapies. Ensituximab (NPC-1C), panitumumab Vectibix , Bevacizumab (Avastin), aflibercept (Zaltrap). Dr. David J. Kerr, MD. Colorectal cancer targeted chemotherapy options. Advanced stage 4 colon cancer targeted chemotherapy. Second opinion confirms that metastatic colorectal cancer diagnosis is correct and complete. Dr. Anton Titov, MD. Second opinion also confirms that chemotherapy cure of colon cancer is possible even in advanced colon cancer. Best treatment for advanced stage 4 colon cancer with metastatic lesions by antiangiogenesis medications. Second opinion helps to choose precision medicine and the best targeted chemotherapy treatment for stage 4 colorectal cancer with liver or lung metastases. Dr. Anton Titov, MD. Get second opinion on advanced colorectal cancer and be confident that your treatment is the best. Best colorectal cancer treatment center for personalized medicine. Dr. David J. Kerr, MD. Video interview with leading expert in metastatic colorectal cancer treatment from Oxford. Colorectal cancer treatment option. EGFR and anti-angiogenesis targeted therapies. ensituximab, panitumumab, Bevacizumab, aflibercept. Dr. Anton Titov, MD.  Targeted therapy for colorectal cancer treatment came to market 10 years ago. Targeted medications are used in combination with classical chemotherapy to treat colon cancer. What could you highlight in use of targeted therapeutic medications in colon cancer and rectal cancer treatment? Dr. David Kerr, MD (Colon cancer oncologist, Oxford). I have been a colorectal cancer doctor for over 30 years. I first started as a young oncology fellow. We only had a single medication, 5 fluorouracil (5-FU), to treat patients with colorectal cancer. Untreated patients with advanced colon cancer or metastatic colorectal cancer had life expectancy around six months. 5-FU (5 fluorouracil) and folinic acid perhaps would extend life expectancy of patients with metastatic colorectal cancer to 12 to 14 months. We now combine targeted therapy with classic chemotherapy medications to treat colorectal cancer. Dr. David J. Kerr, MD. Now median life expectancy for metastatic colorectal cancer is around 24 or 25 months. We have ensituximab (NPC-1C) and Vectibix (panitumumab) for colon cancer. We also have medications that target epidermal growth factor receptor pathway. This has made a difference in improving life expectancy of metastatic colorectal cancer patients. Anti-angiogenesis medications, Bevacizumab (Avastin) and ziv aflibercept (Zaltrap) have a role to play in metastatic colorectal cancer treatment too. But there is no doubt that combination of classic chemotherapy therapy with one of these targeted medications helped. Dr. Anton Titov, MD. It should be used in Line 1 of treatment of colorectal cancer. Dr. David J. Kerr, MD. We moved to predominant use of EGFR inhibitors in KRAS wild-type colorectal cancer patients. We use molecular biology to select suitable patients with colorectal cancer. They would most benefit from these targeted precision chemotherapy medications. Dr. Anton Titov, MD. More advances will be coming in this area of colon cancer treatment. Colorectal cancer new chemotherapy targeted treatment options: EGFR inhibitors and anti-angiogenesis chemotherapy medications. Ensituximab, Ensituximab.